Small Pharma (DMTTF) Stock Price, News & Analysis

Company Overview

Small Pharma is a clinical-stage biotechnology company focused on the discovery and development of next-generation therapeutics inspired by psychedelic compounds. The company applies proprietary medicinal chemistry and formulation technologies to create novel small-molecule derivatives of naturally occurring tryptamines, with the aim of harnessing their potential to treat a variety of neurological and psychiatric disorders.

Its pipeline comprises lead candidates in preclinical development designed to address acute brain injury, neurodegenerative diseases and mood disorders. These molecules are engineered to modulate neural inflammation, promote neuroregeneration and restore synaptic function, with potential applications in conditions such as traumatic brain injury, stroke and treatment-resistant depression.

Headquartered in Oxford, United Kingdom, Small Pharma collaborates with academic research centres and contract research organizations to advance its pharmacology, toxicology and manufacturing programs. The company has secured a portfolio of patent applications to protect its intellectual property across key global markets.

The leadership team brings together experienced professionals from pharmaceutical research, clinical development and operational management, supporting the progression of Small Pharma’s candidates toward human clinical trials. The company’s shares trade on the OTC Markets under the ticker DMTTF.

Key Stats

• Today's Range: $0.11 to $0.11
• 50-Day Range: $0.11 to $0.11
• 52-Week Range: $0.05 to $0.19
• Volume: N/A
• Average Volume: 113,204 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: OTCMKTS:DMTTF
• CIK: N/A
• Web: www.smallpharma.co.uk
• Phone: N/A
• Fax: N/A
• Employees: 13
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A